RANI vs. URGN, NLTX, SBTX, TERN, PGEN, AVIR, ORGO, NKTX, ATAI, and FBLG
Should you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include UroGen Pharma (URGN), Neoleukin Therapeutics (NLTX), Silverback Therapeutics (SBTX), Terns Pharmaceuticals (TERN), Precigen (PGEN), Atea Pharmaceuticals (AVIR), Organogenesis (ORGO), Nkarta (NKTX), Atai Life Sciences (ATAI), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical preparations" industry.
Rani Therapeutics (NASDAQ:RANI) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, profitability and earnings.
Rani Therapeutics has a net margin of 0.00% compared to UroGen Pharma's net margin of -123.61%. UroGen Pharma's return on equity of 0.00% beat Rani Therapeutics' return on equity.
Rani Therapeutics currently has a consensus price target of $11.75, suggesting a potential upside of 61.40%. UroGen Pharma has a consensus price target of $46.67, suggesting a potential upside of 251.41%. Given UroGen Pharma's higher possible upside, analysts clearly believe UroGen Pharma is more favorable than Rani Therapeutics.
In the previous week, UroGen Pharma had 2 more articles in the media than Rani Therapeutics. MarketBeat recorded 9 mentions for UroGen Pharma and 7 mentions for Rani Therapeutics. UroGen Pharma's average media sentiment score of 0.25 beat Rani Therapeutics' score of 0.00 indicating that UroGen Pharma is being referred to more favorably in the news media.
30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of UroGen Pharma shares are owned by institutional investors. 53.3% of Rani Therapeutics shares are owned by insiders. Comparatively, 11.1% of UroGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Rani Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.
Rani Therapeutics has higher earnings, but lower revenue than UroGen Pharma. Rani Therapeutics is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.
UroGen Pharma received 330 more outperform votes than Rani Therapeutics when rated by MarketBeat users. However, 75.86% of users gave Rani Therapeutics an outperform vote while only 73.18% of users gave UroGen Pharma an outperform vote.
Summary
UroGen Pharma beats Rani Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Rani Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rani Therapeutics Competitors List
Related Companies and Tools
